智通财经APP获悉，据报道，如瑞迪博士(RDY.US)首席执行官透露，该公司计划自2026年起在87个国家推出诺和诺德(NVO.US)减肥药Wegovy活性成分司美格鲁肽的仿制药版本。随着该药物全球专利陆续到期，公司已在多个市场启动注册申报程序。
在财报发布会上，首席执行官Erez Israeli将这一计划称为重大里程碑。据悉，诺和诺德上月刚在印度推出Wegovy，起始三档剂量的周治疗费用为50美元起。
如瑞迪博士的仿制药将率先登陆加拿大、巴西和印度等市场。Israeli特别强调，公司还将在诺和诺德未取得专利保护的国家同步推进上市计划。这将标志着如瑞迪博士正式进军GLP-1类药物领域，未来十年随着更多专利到期，公司计划推出多达26种GLP-1疗法。
Israeli指出该药物具有强劲的商业前景，预计司美格鲁肽仿制药可带来数亿美元的增量收入。公司品牌市场部门首席执行官M.V. Ramana表示，将根据各区域市场特点实施分级定价策略，以提升药物可及性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.